Drug costs

Drug costs

The trught about the drug companies: how they deceive us and what to do about it

Text Size: Normal / Medium / Large
Resource Language: 
English
Media Type: 
Paper
Publisher: 
Random House
Publication Date: 
2004
Publication Place: 
New York, NY

Argues that drug companies' claims that high drug prices are necessary to fund research and development are unfounded, but that the money is spend on marketing of products of dubious benefit.

Available From: 
ISBN/ISSN: 
ISBN 0375508465
PHAR.A54 2004
Notes: 
Includes bibliographical references and index.

Is pharmacare a women's issue?

Text Size: Normal / Medium / Large
Resource Language: 
English
Owning Org: 
Canadian Women's Health Network (CWHN)
Media Type: 
Online
Author: 
Penni Mitchell
Publisher: 
Network/Le Réseau
Publication Date: 
1998
Publication Place: 
Winnipeg, MB

Briefly details the positive and negative impacts of a universal pharmacare program for women.

ISBN/ISSN: 
ISSN 14800039

Report of the Royal Commission on the Future of Health Care in Canada: response from the Women and Health Protection (WHP) Worki

Text Size: Normal / Medium / Large
Resource Language: 
English
Media Type: 
Online
Publisher: 
Women and Health Protection Working Group
Publication Date: 
2003

Addresses six themes found primarily in the "Prescription Drugs" and the "Information, Evidence and Ideas" chapters of The Report of the Royal Commission on the Future of Health Care in Canada.

Available From: 

Pharmacare in Canada: issues and opinions

Text Size: Normal / Medium / Large
Resource Language: 
English
Media Type: 
Paper
Online
Author: 
Åke Blomqvist
Jing Xu
Publisher: 
Minister of Public Works and Government Services Canada
Publication Date: 
2001
Publication Place: 
Ottawa, ON

Reviews the weaknesses of private insurance as a response to escalating drug costs, and outlines the case for extending the universal publicly funded health insurance (as defined by the Canada Health Act) to cover prescription drugs. Discusses various options for containing the cost to the public sector, including patient cost sharing, formularies and generic substitution rules, and argues that there is a stronger case in favour of demand-side cost sharing for drugs than for physician services and hospital care. Describes existing provincial/territorial pharmamcare plans and compares them with the pharmacare system proposed by the National Forum on Health (NFH). Suggests that some degree of patient cost sharing would be desirable in the case of drugs, and also that a system with provisions for opting out (allowing citizens to substitute private insurance for the public plan) should be given serious consideration.

ISBN/ISSN: 
HEAS.B54 2001
Health Policy Working Paper Series No. 01-01
ISBN 0662310306

Conference on national approaches to pharmacare: proceedings; January 18-20, 1998

Text Size: Normal / Medium / Large
Resource Language: 
English
Media Type: 
Paper
Author: 
Organizing Committee for the Conference on National Approaches to Pharmacare
Publisher: 
Health Canada Publications
Publication Date: 
1998
Publication Place: 
Ottawa, ON

Looks at how health care dollars are spent on pharmaceuticals and considers ways of ensuring that Canadians have access to the drugs they need. Covers discussions on the strengths and weaknesses of current national and international practices relating to pharmaceutical coverage and the management of benefit plans. Also addresses several key themes involved in the implementation of pharmacare such as public and private sector roles, cost and cost-control issues, drug prescribing practices and drug use, marketing issues and the impact of advertising.

Available From: 
ISBN/ISSN: 
PHAR.O74 1998
Syndicate content